ArticleBMC ophthalmology2025
Phaeoacremonium iranianum - a new corneal pathogen.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diversity of specialized metabolites in Phaeoacremonium species revealed by untargeted metabolomics and bioactivity assays.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPhaeoacremonium is typically found in the environment and can cause diseases in woody plants. It is rarely responsible for infections in humans. CASE PRESENTATION: In this report, we present a case of corneal infection caused by Phaeoacremonium iranianum. Caused a fan-shaped grayish-white ulcer measuring approximately 4 mm×3 mm inferior nasal cornea. The ulcer appeared relatively dry, with noticeable swelling and cloudiness in the surrounding cornea. The visual acuity after infection was 0.25. We started an aggressive antifungal therapy. Our antifungal susceptibility testing revealed the Minimum Inhibitory Concentration of anifengin was 4 µg/ml, Micafengin and carpofungin exceeding 8 µg/ml, fluorocytosine was 32 µg/ml, posaconazole was 1 µg/ml, voriconazole was 0.5 µg/ml, itraconazole was 2 µg/ml, fluconazole was 64 µg/ml, and amphotericin was 0.05 µg/ml. The patient underwent keratectomy combined with antifungal therapy. A month later, the conjunctiva of the right eye was congested, and a 4*4 mm corneal opacity was visible inferior nasal cornea, with local obvious thinning and a little keratic precipitates on the inner skin, and the infection has been controlled.
conclusionsWe detail the progression and treatment of this infection to contribute to the clinical understanding and management of such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.